Insiders seemed unfazed by the additional ~47.7% drop in $LJPC La Jolla Pharmaceutical Company on Jan 7 – as they have been in the market scooping up shares since the company announced preliminary operating results for 2018 and provided expectations for 2019.
Director Kevin Tang has been the biggest buyer scooping up $6,985,285 of stock for his own account.
